Drug Trial Radar · NCT07363265
Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Aug 2, 2028
Study completion May 2, 2029
Sponsor
- Lead sponsor
- Longbio PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.
Conditions
- Complement-mediated Renal Diseases
Interventions
LP-005 InjectionBiological
IV, Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 24-hour urinary protein-to-creatinine ratio (UPCR) in Basket 1 cohortTime frame: Week 24
- Proportion of patients with a ≥25% reduction in serum creatinine (SCr) from baseline in Basket 2 cohortTime frame: Week 24
- Proportion of patients without dialysis requirement in Basket 3 cohortTime frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.